排毒能力的遗传变异是否会影响肝脏生物标志物对肝脏支持补充方案的反应?
Markus Schauer1,2, Susanne Mair2, Michael Keiner1
1Department of Sport Science, German University of Health & Sport (DHGS), 85737 Ismaning, Germany.
International journal of molecular sciences
|October 29, 2025
概括
肝脏支持补充剂改善了排毒生物标志物,并减少了成人体重和BMI. 这些对排毒途径的积极影响,无论排毒能力的遗传变异,都被观察到.
科学领域:
- 营养生物化学 营养生物化学
- 药物基因组学 药物基因组学
- 毒理学 毒理学 毒理学
背景情况:
- 遗传多态性显著影响个体的肝脏排毒能力.
- 尿路生物标志物可以反映II期解毒活动,但对补充剂的基因型特异性反应尚不清楚.
研究的目的:
- 为了研究多成分肝脏支持补充剂对尿路排毒生物标志物的影响.
- 为了确定排毒基因中的遗传多态性是否会影响对补充剂的反应.
主要方法:
- 一项试点研究涉及30名奥地利成年人,他们接受了为期8周的肝脏支持补充剂治疗方案.
- 尿液中的D-葡萄糖酸和mercapturic酸在基线和随访时被测量.
- 参与者在关键解毒基因 (CYP1A1,GSTM1,GSTP1,GSTT1,NQO1) 中的多态基因被基因定型,并分为正常 (NDC) 或有限 (LDC) 解毒能力组.
主要成果:
- 补充剂导致体重和BMI (p <0.05) 的适度降低.
- 观察到尿液中D-葡萄糖酸 (p < 0.05) 和酸 (p < 0.01) 的显著增加.
- 尿路生物标志物和体重/BMI变化的反应在不同排毒基因型组中一致 (p > 0.05).
结论:
- 多种成分的肝脏支持补充剂可能会调节解毒路径.
- 观察到的好处似乎独立于影响排毒能力的遗传多态性.
- 需要进一步的研究,以在更大的队列中证实这些发现.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
179
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
179
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
808
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
808
Hepatic Drug Excretion: Influencing Factors
518
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
518
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
208
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
208
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
210
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
210
Factors Affecting Drug Biotransformation: Biological
513
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
513


